Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL177909 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115598252-A | Method for rapidly detecting DMAP (dimethyl acetamide) residue in docetaxel intermediate | 无锡紫杉药业股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-121318884-A | Docetaxel purification method of intermediate | 无锡紫杉药业股份有限公司 | 2026-01-13 | — | — | CN | disclosed |
| CN-115598253-B | Method for detecting DCC and DCU residues in docetaxel bulk drug | 无锡紫杉药业股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-117007727-A | High performance liquid chromatography method | 上海医药工业研究院有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-115598253-A | Method for detecting DCC and DCU residues in docetaxel bulk drug | 无锡紫杉药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115598252-A | Method for rapidly detecting DMAP (dimethyl acetamide) residue in docetaxel intermediate | 无锡紫杉药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115598252-A | Method for rapidly detecting DMAP (dimethyl acetamide) residue in docetaxel intermediate | 无锡紫杉药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115598252-A | Method for rapidly detecting DMAP (dimethyl acetamide) residue in docetaxel intermediate | 无锡紫杉药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115521229-A | Preparation method of docetaxel four-membered ring opening product | 无锡紫杉药业股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-115197176-A | Preparation method of 7-trichloroethoxycarbonyl docetaxel | 无锡紫杉药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2012156756-A2 | NEW COMPOUNDS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-11-22 | — | — | WO | disclosed |
| EP-2524918-A1 | Imidazopyrazines derivates as kinase inhibitors | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-8106231-B2 | Process for the preparation of (2R,3S)-3-phenylisoserine methyl ester acetate salt | INDENA S.P.A. (IT) | 2012-01-31 | — | — | US | disclosed |
| WO-2011101644-A1 | TRIAZOLO [4, 5 - B] PYRIDIN DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011089400-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
| US-20100168460-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-3-PHENYLISOSERINE METHYL ESTER ACETATE SALT | INDENA S.P.A. (IT) | 2010-07-01 | — | — | US | disclosed |
| WO-2008101608-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-3-PHENYLISOSERINE METHYL ESTER ACETATE SALT | INDENA S.P.A. (IT) | 2008-08-28 | — | — | WO | disclosed |
| EP-1961735-A1 | Process for the preparation of (2r,3s)-3-phenylisoserine methyl ester acetate salt | Indena S.P.A. (IT) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168460-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-3-PHENYLISOSERINE METHYL ESTER ACETATE SALT | SPTSSB, SRR, MTAP | TUBB4A 1266/4885TUBB 428/4885TUBA3C 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.